Rifamycin
Aemcolo (rifamycin) is a small molecule pharmaceutical. Rifamycin was first approved as Aemcolo on 2018-11-16. It is known to target solute carrier organic anion transporter family member 1A2, solute carrier organic anion transporter family member 2B1, solute carrier organic anion transporter family member 1B1, and solute carrier organic anion transporter family member 1B3.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Aemcolo
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Rifamycin sodium
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| AEMCOLO | RedHill Biopharma | N-210910 RX | 2018-11-16 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| aemcolo | New Drug Application | 2021-07-01 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
RIFAMYCIN SODIUM, AEMCOLO, REDHILL | |||
| 2028-11-16 | GAIN | ||
| 2023-11-16 | NCE | ||
ATC Codes
A: Alimentary tract and metabolism drugs
— A07: Antidiarrheals, intestinal antiinflammatory/antiinfective agents
— A07A: Intestinal antiinfectives
— A07AA: Antibiotics, intestinal
— A07AA13: Rifamycin
D: Dermatologicals
— D06: Antibiotics and chemotherapeutics for dermatological use
— D06A: Antibiotics for topical use
— D06AX: Other antibiotics for topical use in atc
— D06AX15: Rifamycin
J: Antiinfectives for systemic use
— J04: Antimycobacterials
— J04A: Drugs for treatment of tuberculosis
— J04AB: Antibiotics, antitubercular
— J04AB03: Rifamycin
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01A: Antiinfective ophthalmologics
— S01AA: Antibiotics, ophthalmologic
— S01AA16: Rifamycin
— S02: Otologicals
— S02A: Antiinfective drugs, otologic
— S02AA: Antiinfectives
— S02AA12: Rifamycin
HCPCS
No data
Clinical
Clinical Trials
118 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Keratoconus | D007640 | EFO_0004223 | H18.6 | 8 | 16 | 23 | 3 | 10 | 51 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | — | — | 1 | 2 | 3 |
| Lactic acidosis | D000140 | EFO_1000036 | E87.20 | — | 1 | 1 | 1 | — | 2 |
| Surgical amputation | D000671 | — | — | — | 1 | — | 1 | ||
| Osteomyelitis | D010019 | EFO_0003102 | M86 | — | — | — | 1 | — | 1 |
| Fatigue | D005221 | HP_0012378 | R53.83 | — | — | — | 1 | — | 1 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | — | — | 1 | — | 1 |
| Lipodystrophy | D008060 | E88.1 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pathologic dilatation | D004108 | — | 4 | 4 | — | 3 | 9 | ||
| Keratitis | D007634 | H16 | — | 2 | 3 | — | — | 3 | |
| Crohn disease | D003424 | EFO_0000384 | K50 | — | — | 1 | — | 1 | 2 |
| Infections | D007239 | EFO_0000544 | — | — | 1 | — | 1 | 2 | |
| Mycobacterium tuberculosis | D009169 | — | — | 1 | — | — | 1 | ||
| Closed head injuries | D016489 | — | — | 1 | — | — | 1 | ||
| Oral ulcer | D019226 | HP_0000155 | — | — | 1 | — | — | 1 | |
| Corneal neovascularization | D016510 | EFO_1000880 | H16.4 | — | 1 | 1 | — | — | 1 |
| Diabetic neuropathies | D003929 | EFO_1000783 | — | — | 1 | — | — | 1 | |
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | 1 | 1 | — | — | — | 2 |
| Chronic pain | D059350 | HP_0012532 | — | 1 | — | — | — | 1 | |
| Compliance | D003187 | — | 1 | — | — | — | 1 | ||
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | 1 | — | — | — | 1 |
| Gastrointestinal microbiome | D000069196 | — | 1 | — | — | — | 1 | ||
| Delirium | D003693 | R41.0 | — | 1 | — | — | — | 1 | |
| Delayed emergence from anesthesia | D055191 | — | 1 | — | — | — | 1 | ||
| Neurocognitive disorders | D019965 | F09 | — | 1 | — | — | — | 1 | |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | 1 | — | — | — | 1 |
| Psoriasis | D011565 | EFO_0000676 | L40 | — | 1 | — | — | — | 1 |
Show 13 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carpal tunnel syndrome | D002349 | EFO_0004143 | G56.0 | 1 | — | — | — | — | 1 |
| Burning mouth syndrome | D002054 | EFO_1000850 | 1 | — | — | — | — | 1 | |
| Corneal ulcer | D003320 | H16.0 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Blood pressure | D001794 | EFO_0004325 | — | — | — | — | 3 | 3 | |
| Healthy volunteers/patients | — | — | — | — | — | 2 | 2 | ||
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | — | 2 | 2 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | — | — | 1 | 1 |
| Pelvic floor disorders | D059952 | — | — | — | — | 1 | 1 | ||
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | — | — | — | 1 | 1 |
| Medication adherence | D055118 | EFO_0006344 | — | — | — | — | 1 | 1 | |
| Ehlers-danlos syndrome | D004535 | Orphanet_98249 | Q79.6 | — | — | — | — | 1 | 1 |
| Glaucoma | D005901 | EFO_0000516 | H40 | — | — | — | — | 1 | 1 |
| Anemia | D000740 | EFO_0004272 | D64.9 | — | — | — | — | 1 | 1 |
Show 4 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | RIFAMYCIN |
| INN | rifamide |
| Description | Rifamycin SV is a member of the class of rifamycins that exhibits antibiotic and antitubercular properties. It has a role as a bacterial metabolite, an antimicrobial agent and an antitubercular agent. It is a member of rifamycins, an acetate ester, a cyclic ketal, a lactam, a macrocycle, a polyphenol and an organic heterotetracyclic compound. It is a conjugate acid of a rifamycin SV(1-). |
| Classification | Small molecule |
| Drug class | antibiotics (Streptomyces strain); antibiotics (rifamycin derivatives) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(cc(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C |
Identifiers
| PDB | — |
| CAS-ID | 6998-60-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL437765 |
| ChEBI ID | 29673 |
| PubChem CID | 6324616 |
| DrugBank | DB11753 |
| UNII ID | TS121H7U7E (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
SLCO1A2
SLCO1A2
SLCO2B1
SLCO2B1
SLCO1B1
SLCO1B1
SLCO1B3
SLCO1B3
Organism
Homo sapiens
Gene name
SLCO1A2
Gene synonyms
OATP, OATP1, OATP1A2, SLC21A3
NCBI Gene ID
Protein name
solute carrier organic anion transporter family member 1A2
Protein synonyms
OATP-1, OATP-A, organic anion transporting polypeptide A, Organic anion-transporting polypeptide 1, Sodium-independent organic anion transporter, solute carrier family 21 (organic anion transporter), member 3, Solute carrier family 21 member 3
Uniprot ID
Mouse ortholog
—
—
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 5,335 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,416 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more